Oncolines Team Joins Symeres

January 10th, 2023|

Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities Nijmegen, the Netherlands: Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), [...]

On-demand webinar on cancer genomics

July 29th, 2022|

Cancer genomics is key to Oncolines’ cancer cell line profiling services and bioinformatics. In PIVOTTalk, a webinar series hosted by the Pivot Park, Jeffrey Kooijman and Tessa de Bitter describe the history [...]

Oncolines News Flash

March 9th, 2022|

First presentation of novel mitotic checkpoint inhibitor BAL0891 data at ESMO TAT congress 2022 At the virtual Targeted Anticancer Therapy (TAT) congress, which was organized by the European Society of Medical Oncology (ESMO) [...]

Oncolines News Flash

March 3rd, 2022|

Oncolines to present detailed profiling of recently approved kinase inhibitors at the ESMO TAT Currently approved small molecule kinase inhibitors act only through a limited number of kinase targets. Well-known targets are EGFR, [...]

Oncolines News Flash

February 4th, 2022|

OncolinesProfiler™ Compound Library is approaching the 200 mark. Clustering analysis via OncolinesProfiler™ compares your compound’s IC50 fingerprint against the cellular activity of other anti-cancer therapeutics. The OncolinesProfiler™ compound library started out as a [...]

Oncolines opens a new screening lab

November 2nd, 2021|

Oncolines is expanding its lab capacity with a new screening lab including cell culture facilities. Oncolines opens a new screening lab Oncolines is expanding its lab [...]

NTRC Precision Medicine Services is now Oncolines

September 28th, 2021|

As an independent company, Oncolines will now be singularly focused on offering the best precision medicine services in oncology and cancer immunotherapy for our clients. Our Oncolines™ cancer cell line panels can identify drug [...]

Case study: Altered drug response in 3D spheroids

May 25th, 2021|

May 25, 2021: A new case study is presented, in which the use of spheroids for the determination of drug sensitivity is highlighted. The figure shows dose-response curves of the KRAS [...]

  • Featured image co-culture assay for paper Grobben et al (2021) Frontiers in Immunology

Tryptophan-metabolizing enzymes in cancer immunology

January 28th, 2021|

January 28, 2021: A new article on the role of tryptophan-metabolizing enzymes in cancer immunology is now online in Frontiers in Immunology (Grobben et al., 2021). The figure shows a co-culture assay of [...]

Predictive approach for clinical response to chemotherapy

December 21st, 2020|

December 21: A new article on malignant ascites as a model for drug sensitivity testing is now online in Oncotarget (den Ouden et al, 2020). New in Oncotarget: Chemotherapy sensitivity [...]

  • website ntrctx.com

New website on small molecules for precision oncology: www.ntrctx.com

December 1st, 2020|

December 01: Read about NTRC Therapeutics translational science platforms and drug discovery projects at www.ntrctx.com. New website on small molecules for precision oncology: www.ntrctx.com Oss, December 01, Targeted therapies [...]

  • Join us at ASH2020

Presentations at ASH2020

November 30th, 2020|

November 30: Join us at ASH2020 for two oral presentations on December 7th, by Jordy van der Zwet and Valentina Cordo. Combination therapies for T-ALL presented at ASH2020 Oss, [...]

NTRC launches new website: www.residencetimer.com

July 31st, 2020|

July 31, 2020: NTRC launches www.residencetimer.com for biochemical assays in drug discovery. Biochemical assays for determination of binding characteristics Oss, July, 31, 2020 – NTRC Precision Medicine Services proudly [...]

  • logo AACR 2020 virtual meeting. NTRC presents a poster on High TDO and IDO1 expression in ovarian cancer-associated cells isolated from malignant ascites

NTRC Presents at AACR Virtual Annual Meeting II

June 23rd, 2020|

June 23, 2020: NTRC presents the poster #5604, titled 'High TDO and IDO1 expression in ovarian cancer-associated cells isolated from malignant ascites' at the AACR Virtual Annual Meeting II. High [...]

  • NTRC will expand its laboratory space

NTRC Expands its Capacity in Molecular Biology Services

May 4th, 2020|

May 04, 2020: NTRC's new laboratory space for Mechanistic Cell Biology. Additional Laboratory Space for Molecular Biology Services Oss, May, 4th, 2020 – Happy to announce that NTRC is [...]

NTRC publishes an association of CTNNB1 mutant status and increased cancer cell line sensitivity to TTK inhibitors

July 28th, 2017|

Normal 0 21 false false false NL X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:Standaardtabel; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";} Oss, July, 27th, 2017 [...]

NTRC launches comparative cancer cell line profiling

September 14th, 2015|

Oss, September, 14th, 2015 – NTRC today announced that it has extended its bioinformatics analysis to its Oncolines™ cancer cell line profiling service. OncolinesProfiler™ involves the comparison of a clients’ compound against more than 100 [...]

NTRC will attend BIO 2014 in San Diego

May 5th, 2014|

Gavin Clark, VP Business Development of NTRC, will attend BIO 2014 Conference held in San Diego from June 21st to June 26th. Gavin Clark will be available to meet with interested parties from pharmaceutical industries [...]

NTRC extends the roll-out of its services Oncolines™ and SynergyFinder™ and the kinase profiling services of Carna Biosciences Inc.

December 10th, 2013|

NTRC delivers its drug discovery capabilities as fee-for-service for development projects of druggable protein target classes. NTRC is also the European representative for Carna Biosciences Inc. for kinase profiling and reverse phase phospho-protein array technology [...]

NTRC starts at the Life Sciences Park Oss

June 6th, 2012|

Oss – 6 June 2012 - Netherlands Translational Research Center B.V. (NTRC) starts operations at the Life Sciences Park Oss, after successful closing its first round of financing. With the financial support of the Brabant [...]